eligibility_summary
Adults (≥18) with MSLN-positive (IHC ≥2+) advanced/metastatic solid tumors after ≥1 line failure or no standard option, measurable disease, ECOG 0–1, adequate organs, life expectancy >12 wks, recovered AEs ≤G1, contraception required. Exclude: recent investigational/anti-tumor/cell therapy, chemo (non-lymphodepletion), steroids >10 mg, anticoagulants, transplants, immunodeficiency/autoimmune, recent vaccines, active CNS mets, serious disease, major cardiac issues, pregnancy, uncontrolled effusions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CHT102, an allogeneic “universal” chimeric antigen receptor T-cell (CAR‑T) therapy targeting mesothelin (MSLN). Type: gene‑modified cellular immunotherapy using donor-derived T lymphocytes. Mechanism of action: the engineered CAR specifically binds MSLN on tumor cells, triggering T‑cell activation and cytotoxic killing (e.g., perforin/granzyme release) independent of native TCR, enabling off‑the‑shelf tumor targeting. Cells/pathways targeted: mesothelin‑expressing tumor cells, activation of CAR-mediated T‑cell signaling leading to immune synapse formation, cytokine release, and apoptosis of MSLN+ cells. Study design: single‑arm, open‑label dose escalation/expansion in adults with MSLN‑positive advanced solid tumors, UCAR‑T infused on Days 1/5/9 at escalating doses (optional 2.5×10^6/kg, then 5×10^6 to 3×10^7 CAR+ cells/kg).